ClinicalTrials.gg
Active, not recruitingNCT04294628Updated Nov 17, 2026Results posted

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

A Phase 1 interventional study of Biopsy Procedure and Biospecimen Collection in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm and Refractory Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI). Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know · 8 judgments

Updated Nov 17, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis — 10 open to participants now, 13 under way, 2 of them phase 3. trastuzumab deruxtecan · Neoplasm Metastasis.

Enrollment
11th of 20
62 · median 69
Started
2020
with 2 others
Phase 1
6 of 20
3 open now
Primary completion
2025-09
later than 1 of 12 live
Registered
7th of 20
by date
Lead sponsor
4 of 20
National Cancer Institute (NCI)

Among the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, this one is the 11th largest by enrollment, is one of 3 that started in 2020, is one of 6 in phase 1, reaches primary completion later than 1 of the 12 other live ones, and was the 7th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

10 of the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This phase I trial studies the biological effects of trastuzumab deruxtecan (DS-8201a) on patients with human epidermal growth factor receptor 2 (HER2) positive cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). DS-8201a works by binding to a protein called HER2 that is present on the surface of tumor cells. This allows DS-8201a to kill the tumor cells by damaging their deoxyribonucleic acid (DNA), resulting in tumor cell death. This study looks at how DS-8201a may affect the levels of certain proteins and immune cells in tumors and how well the drug works against tumor cells by examining cells from a small piece tumor taken before and after DS-8201a is given.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the effects of trastuzumab deruxtecan (DS-8201a) on total Top1 levels in biopsy specimens from patients with human epidermal growth factor receptor 2 (HER2) -expressing advanced solid tumors, at early and late post-treatment time points, thereby establishing the degree and duration of DS-8201 target engagement.

SECONDARY OBJECTIVES:

I. To assess any associations between serum concentrations of DS-8201a and the effects of DS-8201a on total Top1 levels in tumor biopsy specimens.

II. To determine the safety and tolerability of DS-8201a administered intravenously every 3 weeks, in 21-day cycles, at a dose of 5.4 mg/kg.

III. To determine the overall response rate (complete response [CR] + partial response [PR]) for patients administered intravenously with DS-8201a every 3 weeks, in 21-day cycles, at a dose of 5.4 mg/kg.

EXPLORATORY OBJECTIVES:

I. To evaluate the effects of DS-8201a on cluster of differentiation 8 (CD8+) T cell infiltration and activation in tumor, tumor programmed death-ligand 1 (PD-L1) and HER2 expression, and deoxyribonucleic acid (DNA) damage response (DDR) signaling (for example: gamma H2A histone family member X (H2AX), radiation sensitive 51 (RAD51), and phosphorylated [p]Nibrin (NBS1) in biopsy specimens.

II. To examine genomic alterations in circulating tumor DNA (ctDNA) that may be associated with DS-8201a response or resistance.

III. To examine any associations between baseline tumor HER2 amplification or HER2 expression level and response to DS-8201a.

IV. To evaluate the effects of DS-8201a on tumor levels of HER2 and DDR-associated proteins.

V. To examine any tumor genomic alterations that may be associated with resistance to DS-8201a.

VI. To evaluate anti-drug antibodies following administration of DS-8201a.

OUTLINE:

Patients receive trastuzumab deruxtecan intravenously (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography (ECHO) or multi-gated acquisition scan (MUGA), computed tomography (CT) or magnetic resonance imaging (MRI), biopsies, and collection of blood samples throughout the study.

After completion of study treatment, patients are followed up for 40 days.

03

Conditions studied

  • Advanced Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • Refractory Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm

Browse trials for

Keywords

  • Topoisomerase I
  • HER2
  • Antibody-drug conjugate
  • Pharmacodynamics
  • Pharmacology
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have confirmed that is or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
  • Patients must have measurable or evaluable disease
  • Age >= 18 years of age
  • Patients must have human epidermal growth factor receptor 2 ()-positive or HER2-expressing tumors as defined by Clinical Laboratory Improvement Act (CLIA)-certified labs. Patients must have either:

    • A tumor HER2 immunohistochemistry (IHC) score of 1+ or greater (as determined by a CLIA-certified IHC test, per criteria specified) or
    • A tumor with HER2 amplification (as determined by CLIA-certified in situ hybridization [ISH] or a CLIA-certified next-generation sequencing assay)
  • Patients with HER2 mutations are eligible, as are patients with HER2-positive breast cancer
  • Patients must have (ECOG) performance status =\< 1 ( >= 70%)
  • >= 1,500/mcL (within 8 days of enrollment)
  • >= 100,000/mcL (within 8 days of enrollment)
  • Leukocytes >= 3,000/mcL (within 8 days of enrollment)
  • >= 9 g/dL (>= 8.0 g/dL for gastric cancer [GC] only) (within 8 days of enrollment)
  • Serum albumin >= 2.5 g/dL group-specific component (GC only) (within 8 days of enrollment)
  • Total =\< 1.5 x institutional (=\< 3 x upper limit of normal in the presence of documented Gilbert's syndrome or liver metastases at baseline) (within 8 days of enrollment)
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 3 x institutional upper limit of normal OR =\< 5 x institutional upper limit of normal for patients with liver metastases at baseline (within 8 days of enrollment)
  • Creatinine =\< 1.5 x institutional upper limit of normal OR >= 60 mL/min/1.73 m\^2 for patients with creatinine levels above 1.5 x institutional normal (within 8 days of enrollment)
  • No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment
  • No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 1 week prior to screening assessment
  • (INR)/prothrombin time (PT) and either partial thromboplastin or activated partial thromboplastin time (aPTT) =\< 1.5 x upper limit of normal (ULN)
  • Ability to understand and the willingness to sign a written document
  • Willingness to provide blood samples for research purposes
  • Patients must have a lesion or lesions amenable to and must be willing to undergo 3 core needle biopsy procedures for research purposes
  • Patients must have (LVEF) >= 50% by either an echocardiogram (ECHO), multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI) scan within 28 days prior to enrollment
  • Patients receiving standard of care androgen deprivation treatment (surgical castration versus luteinizing hormone-releasing hormone [LHRH] agonist or antagonist treatment) are eligible to participate in the trial. Patients receiving LHRH agonist or antagonist may continue treatment throughout the duration of this study
  • Patients who are (HIV) positive may participate IF they meet the following eligibility requirements:

    • They must be stable on their anti-retroviral regimen, and they must be healthy from an human immunodeficiency virus (HIV) perspective
    • They must have a cluster of differentiation 4 (CD4) count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a \< 200 cells/uL over the past 2 years, unless it was deemed related to the cancer and/or immunotherapy-induced bone marrow suppression

      • For patients who have received chemotherapy in the past 6 months, a CD4 count \< 250 cells/ul during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy
    • They must have an undetectable viral load and a CD4 count >= 250 cells/uL within 8 days of enrollment
    • They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for >= 1 month after treatment of the brain metastases
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • The effects of trastuzumab deruxtecan (DS-8201a) on the developing human fetus are unknown. For this reason and because HER2 antibodies conjugated to topoisomerase 1 inhibitor agents are known to be teratogenic, women of and men must agree to use adequate (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation and for at least 7 months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a administration
  • Women of non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] > 40 mIU/mL and estradiol \< 40 pg/mL [\< 147 pmol/L] is confirmatory) are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method
  • Subjects must not freeze, donate, or retrieve for their own use ova or sperm starting at screening, throughout the study period, and for at least 4.5 months after the final study drug administration. Preservation of sperm or ova should be considered prior to enrollment in this study
  • Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DS-8201a, breastfeeding should be discontinued if the mother is treated with DS-8201a

Exclusion criteria

Exclusion Criteria:

  • Patients who have had:

    • Chemotherapy (including antibody drug therapy, retinoid therapy, hormonal therapy for cancer-with the exception of standard of care androgen deprivation treatment) within:

      • 4 weeks or five half-lives, whichever is shorter, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel or
      • 6 weeks for nitrosoureas or mitomycin C or
    • Immunotherapy, including monoclonal antibody therapy, within 4 weeks
  • Patients with any of the following pulmonary-related illnesses:

    • A history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required , current ILD/pneumonitis, or for whom suspected ILD/pneumonitis cannot be ruled out by imaging at screening
    • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the study enrollment, severe asthma, severe [COPD] grade 3-4 per Global Initiative for Obstructive Lung Disease [GOLD] criteria, restrictive lung disease, pleural effusion, etc.), and any , connective tissue, or inflammatory disorders with potential pulmonary involvement (i.e., Rheumatoid arthritis, Sjogren's, sarcoidosis, etc.), or prior pneumonectomy
  • Patients who have had radiation therapy within 4 weeks (or palliative stereotactic radiation therapy within 2 weeks)
  • Patients who have had a major surgery within 4 weeks
  • Patients who are receiving any other agents
  • Patients with a medical history of myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (CHF) ( class II to IV), or with troponin levels consistent with myocardial infarction (as defined according to the assay manufacturer) 28 days prior to enrollment
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to DS-8201a (e.g., other topoisomerase I inhibitors) or the inactive ingredients in the drug product
  • Patients who have a history of severe reactions to other monoclonal antibodies
  • Patients with a Fridericia's formula- interval (QTcF) prolongation to > 470 ms (females) or > 450 ms (males) based on average of the screening triplicate 12-lead (ECG)
  • Patients with spinal cord compression or clinically active central nervous system , defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
  • Patients with an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
  • Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to grade =\< 1 or baseline. Subjects with chronic grade 2 toxicities (e.g., grade 2 chemotherapy-induced neuropathy) may be eligible per the discretion of the investigator after consultation with the sponsor medical monitor or designee. Subjects should no longer be symptomatic nor require treatment with corticosteroids or anticonvulsants and must have recovered from the acute toxic effect of radiotherapy
  • Patients with substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation of the subject or evaluation of the clinical study in the opinion of the investigator
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because DS-8201a is a antibody conjugated to a topoisomerase 1 inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DS-8201a, breastfeeding should be discontinued if the mother is treated with DS-8201a
  • Patients are not allowed to receive chloroquine/hydroxychloroquine. Patients receiving chloroquine/hydroxychloroquine require a of > 14 days
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Treatment (trastuzumab deruxtecan)

    Patients receive trastuzumab deruxtecan intravenous (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiogram (ECHO) or multi-gated acquisition scan (MUGA), computed tomography (CT) or magnetic resonance imaging (MRI), biopsies, and collection of blood samples throughout the study.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Magnetic Resonance Imaging · Procedure: Multigated Acquisition Scan · Biological: Trastuzumab Deruxtecan

Interventions

  • ProcedureBiopsy Procedure

    Undergo biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureComputed Tomography

    Undergo computerized tomography (CT) scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureEchocardiography Test

    Undergo echocardiogram (ECHO)

    Also known as: EC, Echocardiography, Echocardiogram

  • ProcedureMagnetic Resonance Imaging

    Undergo magnetic resonance imaging (MRI)

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedureMultigated Acquisition Scan

    Undergo multi-gated acquisition scan (MUGA)

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • Given intravenous (IV)

    Also known as: DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516

06

What researchers measure

Primary outcomes

  1. Change in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time Points

    Change (i.e., decrease) in total TOP1 protein as measured by the percentage of nuclear area staining positive (%NAP) for TOP1 in biopsies collected after trastuzumab deruxtecan (DS-8201a) treatment compared to baseline biopsies using a quantitative immunofluorescence assay. We do not have any evidence regarding whether an increase or decrease in total TOP1 %NAP after treatment increases the likelihood of the tumor responding to the drug.

    Time frame: (Early post treatment compared to baseline) - Up to day 7 of cycle 1 (one cycle = 21 days), for an average of 3.2 days; (late post treatment compared to baseline) Day 1 of cycle 3, for an average of 47 days

  2. Tumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) Treatment

    The change in the number of active immune cells in each participants' tumor after treatment with trastuzumab deruxtecan (DS-8201a) compared with baseline, as measured by the number of cells per square millimeter within the tumor that stain positive for both the Cluster of Differentiation 8 (CD8+) protein and the T-cell receptor T3 zeta chain (CD3ζ) protein phosphorylated at Tyrosine 142 (CD3ζ pY142+) using a quantitative immunofluorescence assay. Larger or increasing numbers of active immune cells in the tumor are thought to increase the likelihood of the tumor responding to the drug.

    Time frame: Baseline compared to Day 1 of cycle 3 (1 cycle = 21 days), for an average of 47 days

Secondary outcomes

  1. Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and Change in Total TOP1 Levels in Tumor Biopsies

    The association between serum concentrations of trastuzumab deruxtecan (DS-8201a) and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a serum concentration at the timepoint closest to the biopsy and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy.

    Time frame: Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days

  2. Correlation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)

    The association between the maximum serum concentration of trastuzumab deruxtecan (DS-8201a) and the initial change in tumor cells' TOP1 covalent complex (TOP1cc) levels will be assessed by computing the sample correlation between the highest DS-8201a serum concentration observed for each participant during cycle 1 of treatment and the initial change in tumor cells with TOP1cc (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy

    Time frame: Baseline compared to cycle 1 (one cycle = 21 days), 2-4 days post-day 1 dose

  3. Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor Biopsies

    Area Under the Curve (AUC) is a calculated estimate of the serum concentration of Trastuzumab Deruxtecan (DS-8201a) over time. It is used to characterize the overall exposure over a time interval. The association between participant trastuzumab deruxtecan (DS-8201a) AUC and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a AUC and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy.

    Time frame: Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days

  4. Number of Participants With Grade 2 and Higher Treatment-related Adverse Events, Reporting Only the Worst Grade That is at Least Possibly Related to Study Drugs for Each Participant

    Grades 2 and higher adverse events were measured using the Common Terminology Criteria for Adverse Events (CTCAEv5.0). Grade 2 moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

    Time frame: From the start of the treatment until disease progression/recurrence, an average of 6.8 months

  5. Overall Response Rate

    The overall response rate (complete response + partial response) among eligible participants who have received at least one dose of trastuzumab deruxtecan (DS-8201a). A 95% confidence interval for this response rate will also be computed. For this analysis, response classifications will follow Response Evaluation Criteria in Solid Tumors version 1.1 guidelines. Complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1cm). Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Overall response rate is the combination of complete and partial responses.

    Time frame: From the start of the treatment until disease progression/recurrence, an average of 6.8 months.

Other outcomes

  1. Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

    Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months,

07

Results

Posted Nov 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Started62
Started treatment61
Completed61
Not completed1
Withdrew: Did not go on to receive treatment.1

Outcome measures

PrimaryChange in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time Points

Change (i.e., decrease) in total TOP1 protein as measured by the percentage of nuclear area staining positive (%NAP) for TOP1 in biopsies collected after trastuzumab deruxtecan (DS-8201a) treatment compared to baseline biopsies using a quantitative immunofluorescence assay. We do not have any evidence regarding whether an increase or decrease in total TOP1 %NAP after treatment increases the likelihood of the tumor responding to the drug.

Time frame:
(Early post treatment compared to baseline) - Up to day 7 of cycle 1 (one cycle = 21 days), for an average of 3.2 days; (late post treatment compared to baseline) Day 1 of cycle 3, for an average of 47 days
Reported as:
Mean · %NAP
Change in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time Points
%NAPChanges At Early Post-Treatment (Up to Day 7 of Cycle 1)Change At Late Post-Treatment (Up to Day 1 of Cycle 3)
Change in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time Points-4.5 ± 5.9-1.3 ± 3.8
PrimaryTumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) Treatment

The change in the number of active immune cells in each participants' tumor after treatment with trastuzumab deruxtecan (DS-8201a) compared with baseline, as measured by the number of cells per square millimeter within the tumor that stain positive for both the Cluster of Differentiation 8 (CD8+) protein and the T-cell receptor T3 zeta chain (CD3ζ) protein phosphorylated at Tyrosine 142 (CD3ζ pY142+) using a quantitative immunofluorescence assay. Larger or increasing numbers of active immune cells in the tumor are thought to increase the likelihood of the tumor responding to the drug.

Time frame:
Baseline compared to Day 1 of cycle 3 (1 cycle = 21 days), for an average of 47 days
Reported as:
Mean · cells per millimeter squared(cells/mm^2)
Tumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) Treatment
cells per millimeter squared(cells/mm^2)Change At Late Post-Treatment (Up to Day 1 of Cycle 3)
Tumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) Treatment-0.4 ± 12.7
SecondaryCorrelation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and Change in Total TOP1 Levels in Tumor Biopsies

The association between serum concentrations of trastuzumab deruxtecan (DS-8201a) and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a serum concentration at the timepoint closest to the biopsy and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy.

Time frame:
Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
Reported as:
Number · Correlation Coefficient
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and Change in Total TOP1 Levels in Tumor Biopsies
Correlation CoefficientTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and Change in Total TOP1 Levels in Tumor Biopsies0.24
Statistical analysis
  • Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles · Pearson correlation: 0.24
SecondaryCorrelation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)

The association between the maximum serum concentration of trastuzumab deruxtecan (DS-8201a) and the initial change in tumor cells' TOP1 covalent complex (TOP1cc) levels will be assessed by computing the sample correlation between the highest DS-8201a serum concentration observed for each participant during cycle 1 of treatment and the initial change in tumor cells with TOP1cc (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy

Time frame:
Baseline compared to cycle 1 (one cycle = 21 days), 2-4 days post-day 1 dose
Reported as:
Number · Correlation Coefficient
Correlation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)
Correlation CoefficientTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Correlation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)0.17
Statistical analysis
  • Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles · Pearson correlation: 0.17
SecondaryCorrelation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor Biopsies

Area Under the Curve (AUC) is a calculated estimate of the serum concentration of Trastuzumab Deruxtecan (DS-8201a) over time. It is used to characterize the overall exposure over a time interval. The association between participant trastuzumab deruxtecan (DS-8201a) AUC and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a AUC and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy.

Time frame:
Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
Reported as:
Number · Correlation Coefficient
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor Biopsies
Correlation CoefficientTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor BiopsiesNA
SecondaryNumber of Participants With Grade 2 and Higher Treatment-related Adverse Events, Reporting Only the Worst Grade That is at Least Possibly Related to Study Drugs for Each Participant

Grades 2 and higher adverse events were measured using the Common Terminology Criteria for Adverse Events (CTCAEv5.0). Grade 2 moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

Time frame:
From the start of the treatment until disease progression/recurrence, an average of 6.8 months
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 and Higher Treatment-related Adverse Events, Reporting Only the Worst Grade That is at Least Possibly Related to Study Drugs for Each Participant
ParticipantsTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Abdominal pain, grade 22
Abdominal pain, grade 31
Activated partial thromboplastin time prolonged, grade 21
Alanine aminotransferase increased, grade 21
Alkaline aminotransferase increased, grade 21
Alopecia, grade 25
Anemia, grade 215
Anemia, grade 314
Anorexia, grade 28
Anorexia, grade 32
Anxiety, grade 21
Ascites, grade 21
Aspartate aminotransferase increased, grade 22
Aspartate aminotransferase increased, grade 31
Blood bilirubin increased, grade 21
Constipation, grade 23
Cough, grade 21
Creatinine increased, grade 23
Dehydration, grade 22
Dehydration, grade 31
Diarrhea, grade 29
Diarrhea, grade 33
Dysgeusia, grade 21
Dyspepsia, grade 22
Dyspnea, grade 22
Dyspnea, grade 31
Edema limbs, grade 21
Ejection fraction decreased, grade 21
Fall, grade 31
Fatigue, grade 218
Fatigue, grade 35
Fever, grade 22
Flu like symptoms, grade 21
Gastroesophageal reflux disease, grade 21
Generalized muscle weakness, grade 24
Generalized muscle weakness, grade 31
Hepatobiliary disorders - Other Liver fibrosis, grade 21
Hiccups, grade 21
Hypertension, grade 31
Hypokalemia, grade 21
Hypokalemia, grade 32
Hypomagnesemia, grade 21
Hyponatremia, grade 23
Hyponatremia, grade 31
Hypophosphatemia, grade 21
Hypotension, grade 21
Hypoxia, grade 21
Hypoxia, grade 31
Lymphocyte count decreased, grade 28
Lymphocyte count decreased, grade 36
Lymphocyte count decreased, grade 41
Mucositis grade 23
Nausea, grade 222
Nausea, grade 31
Neutrophil count decreased, grade 27
Neutrophil count decreased, grade 33
Neutrophil count decreased, grade 42
Platelet count decreased, grade 22
Platelet count decreased, grade 31
Platelet count decreased, grade 41
Pleural effusion, grade 21
Pneumonitis, grade 29
Pneumonitis, grade 31
Presyncope, grade 21
Rash maculo-papular, grade 22
Skin infection, grade 21
Syncope, grade 31
Thrush, grade 21
Urinary tract infection, grade 22
Vomiting, grade 27
Weight loss, grade 25
White blood cell decreased, grade 217
White blood cell decreased, grade 32
Grade 5 Treatment Related Adverse Events0
SecondaryOverall Response Rate

The overall response rate (complete response + partial response) among eligible participants who have received at least one dose of trastuzumab deruxtecan (DS-8201a). A 95% confidence interval for this response rate will also be computed. For this analysis, response classifications will follow Response Evaluation Criteria in Solid Tumors version 1.1 guidelines. Complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1cm). Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Overall response rate is the combination of complete and partial responses.

Time frame:
From the start of the treatment until disease progression/recurrence, an average of 6.8 months.
Reported as:
Number · Percentage of participants
Overall Response Rate
Percentage of participantsTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Overall Response Rate24.6 (14.5 to 37.3)
Other pre-specifiedNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months,
Reported as:
Count of participants · Participants
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
ParticipantsTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)61

Adverse events

Collected over All-Cause Mortality was monitored/assessed an average of 4.9 months. Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles5/62 (8.1%)37/61 (60.7%)61/61 (100%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
AnemiaBlood and lymphatic system disorders9/61
FatigueGeneral disorders7/61
DiarrheaGastrointestinal disorders5/61
NauseaGastrointestinal disorders5/61
DyspneaRespiratory, thoracic and mediastinal disorders4/61
Urinary tract infectionInfections and infestations4/61
VomitingGastrointestinal disorders4/61
FeverGeneral disorders3/61
HypoxiaRespiratory, thoracic and mediastinal disorders3/61
Neutrophil count decreasedInvestigations3/61
Most frequent other events
Showing 10 of 252
Most frequent other events
EventTrastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
NauseaGastrointestinal disorders53/61
AnemiaBlood and lymphatic system disorders46/61
FatigueGeneral disorders41/61
HypoalbuminemiaMetabolism and nutrition disorders35/61
HyperglycemiaMetabolism and nutrition disorders34/61
HyponatremiaMetabolism and nutrition disorders33/61
Alkaline phosphatase increasedInvestigations31/61
AnorexiaMetabolism and nutrition disorders31/61
DiarrheaGastrointestinal disorders31/61
VomitingGastrointestinal disorders31/61

Baseline characteristics

Baseline characteristics data collected for all enrolled participants (N=62), including those enrolled and consented but not treated (n=1) are included here.

Age, Categorical
Age, Categorical(Participants)Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
<=18 years0
Between 18 and 65 years31
>=65 years31
Age, Continuous
Age, Continuous(years)Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Mean65.5 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Female49
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
Hispanic or Latino2
Not Hispanic or Latino57
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American12
White46
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles
United States62
08

Study locations

6 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — National Cancer Institute (NCI) is committed to sharing data in accordance with National Institutes of Health (NIH) policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: At the time of publication or shortly thereafter.

Access criteria: Data will be shared through a National Institutes of Health (NIH) funded or approved public repository: clinicaltrials.gov and Biomedical Translational Research Information System (BTRIS). Approved outside collaborators under appropriate individual agreements. Publication and/or public presentations.

Data sharing details ↗ · grants.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Sep 2025, 60 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

Of 209 non-industry phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 60 months is close to that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2020
First posted
Mar 4, 2020
StartActual
Sep 1, 2020
Primary completionActual
Sep 2, 2025
CompletionEst.
Jan 19, 2027
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Eligibility
6 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatients must have human epidermal growth factor receptor 2 (HER2)-positive or HER2-expressing tumors as defined by Clinical Laboratory Improvement Act (CLIA)-certified labs. Patients must have either:
  • EditedSerum albumin >= 2.5 g/dL group-specific component (GC only) (within 8 days of enrollment)
  • EditedPatients must have left ventricular ejection fraction (LVEF) >= 50% by either an echocardiogram (ECHO), multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI) scan within 28 days prior to enrollment
  • EditedThey must be stable on their anti-retroviral regimen, and they must be healthy from an human immunodeficiency virus (HIV) perspective
  • EditedThey must have a cluster of differentiation 4 (CD4) count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/uL over the past 2 years, unless it was deemed related to the cancer and/or immunotherapy-induced bone marrow suppression
  • EditedThe effects of trastuzumab deruxtecan (DS-8201a) on the developing human fetus are unknown. For this reason and because HER2 antibodies conjugated to topoisomerase 1 inhibitor agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation and for at least 7 months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a administration
Exclusion criteria
  • EditedPatients with an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
Nov 17, 2026
Primary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedChange in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time PointsTime frame: (Early post treatment compared to baseline) - Up to day 7 of cycle 1 (one cycle = 21 days), for an average of 3.2 days; (late post treatment compared to baseline) Day 1 of cycle 3, for an average of 47 days
  • AddedTumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) TreatmentTime frame: Baseline compared to Day 1 of cycle 3 (1 cycle = 21 days), for an average of 47 days
  • RemovedTotal topoisomerase 1 (Top1)Time frame: Up to day 1 of cycle 3 (each cycle is 21 days) or optionally, up to time of disease progression or restaging follow-up
  • RemovedTumor immune microenvironment responseTime frame: Up to day 1 of cycle 3 (each cycle is 21 days) or optionally, up to time of disease progression or restaging follow-up
Nov 17, 2026
Secondary outcomes
2 edited, 4 added, 1 removed
What changed in the outcomes
  • EditedAssociation between serum concentrations of Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and total Top1 levelsChange in tumor biopsiesTotal TOP1 Levels in Tumor BiopsiesTime frame: Up to day 1 of cycle 3 (each cycle is 21 days) or optionally, up to time of disease progression or restaging follow-up → Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
  • EditedOverall response rateResponse RateTime frame: From the start of the treatment until disease progression/recurrence → From the start of the treatment until disease progression/recurrence, an average of 6.8 months.
  • AddedCorrelation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)Time frame: Baseline compared to cycle 1 (one cycle = 21 days), 2-4 days post-day 1 dose
  • AddedCorrelation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor BiopsiesTime frame: Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
  • AddedNumber of Participants With Grade 2 and Higher Treatment-related Adverse Events, Reporting Only the Worst Grade That is at Least Possibly Related to Study Drugs for Each ParticipantTime frame: From the start of the treatment until disease progression/recurrence, an average of 6.8 months
  • RemovedIncidence of adverse eventsTime frame: Up to 30 days post-treatment
  • Addedother outcomeNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)Time frame: Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months,
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Eligibility 6 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients must have human epidermal growth factor receptor 2 (HER2)-positive or HER2-expressing tumors as defined by Clinical Laboratory Improvement Act (CLIA)-certified labs. Patients must have either:
    • EditedSerum albumin >= 2.5 g/dL group-specific component (GC only) (within 8 days of enrollment)
    • EditedPatients must have left ventricular ejection fraction (LVEF) >= 50% by either an echocardiogram (ECHO), multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI) scan within 28 days prior to enrollment
    • EditedThey must be stable on their anti-retroviral regimen, and they must be healthy from an human immunodeficiency virus (HIV) perspective
    • EditedThey must have a cluster of differentiation 4 (CD4) count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/uL over the past 2 years, unless it was deemed related to the cancer and/or immunotherapy-induced bone marrow suppression
    • EditedThe effects of trastuzumab deruxtecan (DS-8201a) on the developing human fetus are unknown. For this reason and because HER2 antibodies conjugated to topoisomerase 1 inhibitor agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation and for at least 7 months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a administration
    Exclusion criteria
    • EditedPatients with an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
    Primary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedChange in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time PointsTime frame: (Early post treatment compared to baseline) - Up to day 7 of cycle 1 (one cycle = 21 days), for an average of 3.2 days; (late post treatment compared to baseline) Day 1 of cycle 3, for an average of 47 days
    • AddedTumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) TreatmentTime frame: Baseline compared to Day 1 of cycle 3 (1 cycle = 21 days), for an average of 47 days
    • RemovedTotal topoisomerase 1 (Top1)Time frame: Up to day 1 of cycle 3 (each cycle is 21 days) or optionally, up to time of disease progression or restaging follow-up
    • RemovedTumor immune microenvironment responseTime frame: Up to day 1 of cycle 3 (each cycle is 21 days) or optionally, up to time of disease progression or restaging follow-up
    Secondary outcomes 2 edited, 4 added, 1 removed
    What changed in the outcomes
    • EditedAssociation between serum concentrations of Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and total Top1 levelsChange in tumor biopsiesTotal TOP1 Levels in Tumor BiopsiesTime frame: Up to day 1 of cycle 3 (each cycle is 21 days) or optionally, up to time of disease progression or restaging follow-up → Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
    • EditedOverall response rateResponse RateTime frame: From the start of the treatment until disease progression/recurrence → From the start of the treatment until disease progression/recurrence, an average of 6.8 months.
    • AddedCorrelation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)Time frame: Baseline compared to cycle 1 (one cycle = 21 days), 2-4 days post-day 1 dose
    • AddedCorrelation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor BiopsiesTime frame: Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
    • AddedNumber of Participants With Grade 2 and Higher Treatment-related Adverse Events, Reporting Only the Worst Grade That is at Least Possibly Related to Study Drugs for Each ParticipantTime frame: From the start of the treatment until disease progression/recurrence, an average of 6.8 months
    • RemovedIncidence of adverse eventsTime frame: Up to 30 days post-treatment
    • Addedother outcomeNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)Time frame: Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months,
    + 5 other changes: verification date, description, conditions, arm descriptions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04294628
Responsible party
Sponsor
First posted
Mar 4, 2020
Start date
Sep 1, 2020
Primary completion
Sep 2, 2025
Completion
Jan 19, 2027 (estimated)
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Sarah Shin
principal investigator · National Cancer Institute LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion